<?xml version="1.0" encoding="UTF-8"?>
<p id="p0100">Preliminary studies of glucocorticoid therapy in COVID-19 to date present mixed results regarding their effects on mortality, clinical parameters, and length of stay.
 <xref rid="bib67" ref-type="bibr">
  <sup>67</sup>
 </xref> However, a 6425-patient open-label RCT of low- to moderate-dose dexamethasone reported reductions in 28-day mortality in one-third of patients receiving mechanical ventilation (rate ratio, 0.64; 95% confidence interval, 0.51 to 0.81) and one-fifth of patients on oxygen support without ventilation (rate ratio, 0.82; 95% confidence interval, 0.72 to 0.94).
 <xref rid="bib68" ref-type="bibr">
  <sup>68</sup>
 </xref>
</p>
